HK1051327A1 - Pharmaceutical compositions for inhibiting angiogenesis by pedf fragments - Google Patents

Pharmaceutical compositions for inhibiting angiogenesis by pedf fragments

Info

Publication number
HK1051327A1
HK1051327A1 HK03103665A HK03103665A HK1051327A1 HK 1051327 A1 HK1051327 A1 HK 1051327A1 HK 03103665 A HK03103665 A HK 03103665A HK 03103665 A HK03103665 A HK 03103665A HK 1051327 A1 HK1051327 A1 HK 1051327A1
Authority
HK
Hong Kong
Prior art keywords
pedf
tissue
tumor
growth
pharmaceutical compositions
Prior art date
Application number
HK03103665A
Other languages
English (en)
Inventor
Noel P Bouck
Paul R Gillis
Veronica M Stellmach
David W Dawson
Susan E Crawford
Olga Volpert
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/603,478 external-priority patent/US6797691B1/en
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of HK1051327A1 publication Critical patent/HK1051327A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03103665A 2000-02-23 2003-05-23 Pharmaceutical compositions for inhibiting angiogenesis by pedf fragments HK1051327A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51168300A 2000-02-23 2000-02-23
US09/603,478 US6797691B1 (en) 1997-07-23 2000-06-23 Methods and compositions for inhibiting angiogenesis
PCT/US2001/005915 WO2001062725A2 (fr) 2000-02-23 2001-02-22 Procedes et compositions permettant d'inhiber l'angiogenese

Publications (1)

Publication Number Publication Date
HK1051327A1 true HK1051327A1 (en) 2003-08-01

Family

ID=27057305

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103665A HK1051327A1 (en) 2000-02-23 2003-05-23 Pharmaceutical compositions for inhibiting angiogenesis by pedf fragments

Country Status (9)

Country Link
EP (1) EP1265627B1 (fr)
JP (1) JP2004516001A (fr)
AT (1) ATE413185T1 (fr)
AU (1) AU2001239855A1 (fr)
CA (1) CA2401096A1 (fr)
DE (1) DE60136444D1 (fr)
ES (1) ES2316437T3 (fr)
HK (1) HK1051327A1 (fr)
WO (1) WO2001062725A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028559A1 (fr) * 2002-09-26 2004-04-08 The Board Of Trustees Of The University Of Illinois Fragments anti-angiogeniques du facteur derive de l'epithelium pigmentaire (pedf)
AU2004285562B2 (en) * 2003-10-29 2011-06-09 The Johns Hopkins University Pigment epithelium-derived factor, novel biological activity and methods of use
AU2004308484A1 (en) * 2003-12-23 2005-07-14 The Trustees Of The University Of Pennsylvania Compositions and methods for combined therapy of disease
WO2006046584A1 (fr) * 2004-10-26 2006-05-04 Santen Pharmaceutical Co., Ltd. Remède pour des traumatismes de cellules visuelles
JP5017535B2 (ja) * 2006-01-23 2012-09-05 株式会社アップウェル 脱毛抑制または発毛促進用組成物
ES2329636B2 (es) * 2006-02-17 2010-07-26 Universitat De Valencia, Estudi General (Participa Con El 70%) Uso del factor pedf para inducir la auto-renovacion de celulas madre.
US20110092427A1 (en) 2008-03-18 2011-04-21 National University Corporation Hokkaido Universit y Polypeptide and pharmaceutical composition containing the polypeptide
EP2486128A4 (fr) * 2009-10-08 2013-10-09 Neurotech Usa Inc Utilisation du pedf dans un système d'administration à base de cellules encapsulées
JP6484174B2 (ja) * 2012-09-19 2019-03-20 マクカイ メモリアル ホスピタル 皮膚老化を予防及び／又は改善するためのｐｅｄｆ−由来ポリペプチドの使用
JP2018502061A (ja) * 2014-11-24 2018-01-25 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔ Ａｔ Ｔｅｌ Ａｖｉｖ Ｕｎｉｖｅｒｓｉｔｙ Ｌｔｄ． 子宮筋腫の治療のための色素上皮由来因子（ｐｅｄｆ）
WO2017189715A1 (fr) 2016-04-26 2017-11-02 Northwestern University Peptides du facteur dérivé de l'épithélium pigmentaire modifié (pedf) et leurs utilisations pour le traitement de maladies néovasculaires, de maladies inflammatoires, du cancer et pour la cytoprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2137377C (fr) * 1992-06-04 2011-03-08 Lincoln V. Johnson Facteur neurotrophique derive d'un epithelium pigmentaire de la retine
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
WO1999004806A1 (fr) * 1997-07-23 1999-02-04 Northwestern University Procedes et compositions pour inhiber l'angiogenese

Also Published As

Publication number Publication date
EP1265627A2 (fr) 2002-12-18
ATE413185T1 (de) 2008-11-15
EP1265627A4 (fr) 2003-04-23
WO2001062725A3 (fr) 2002-03-21
CA2401096A1 (fr) 2001-08-30
EP1265627B1 (fr) 2008-11-05
DE60136444D1 (de) 2008-12-18
ES2316437T3 (es) 2009-04-16
WO2001062725A2 (fr) 2001-08-30
AU2001239855A1 (en) 2001-09-03
JP2004516001A (ja) 2004-06-03

Similar Documents

Publication Publication Date Title
HK1051327A1 (en) Pharmaceutical compositions for inhibiting angiogenesis by pedf fragments
CA2298018A1 (fr) Procedes et compositions pour inhiber l'angiogenese
EP1100870A4 (fr) Amelioration du fonctionnement cardiaque par transplantation de cellules souches mesenchymateuses
IL192762A0 (en) Method for identifying cell differentiation factors
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2001036589A3 (fr) Systeme immunitaire humain ex vivo
MXPA03001914A (es) Matrices basadas en fibrina electroprocesada y tejidos.
WO2001082870A3 (fr) Methode d'activation uniquement du recepteur-3 du facteur de croissance des cellules endotheliales vasculaires et ses utilisations
PL323256A1 (en) Angiostatin fragments and angiostatin aggregate and method of using them
Poulin et al. Response of symbiotic endomycorrhizal fungi to estrogens and antiestrogens
WO2002047673A3 (fr) Methodes et compositions pour le traitement d'etats pathologiques associes a la neovascularisation
IL123642A0 (en) Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration
DE69926251D1 (de) Verfahren zum vernichten von tumoren und tumor-assoziierten endothelialzellen mit adenoviralen mutanten
Sant'Ana et al. Rat skin wound healing induced by alternagin‐C, a disintegrin‐like, Cys‐rich protein from Bothrops alternatus venom
Speirs et al. Paracrine control of differentiation in the alveolar carcinoma, A549, by human foetal lung fibroblasts
NO882854L (no) Korreksjon med dobbeltraadet rna av avvikende metabolske spor forbundet med ukontrollerte vekstsykluser for tumorceller og virus.
CA2546149A1 (fr) Modele d'angiogenese tumorale in vitro
TW200515914A (en) Compositions containing an active fraction isolated from Lycium barbarum and methods of using the same
TW200515915A (en) Extract of Trapa natans and methods of using the same
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
WO2001074296A3 (fr) Traitement de tumeurs non solides chez des mammiferes au moyen d'antagonistes de recepteur de facteur de croissance endothelial vasculaire
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
WO2002098278A3 (fr) Voie de differenciation de fibrocytes sanguins peripheriques et migration vers des sites leses
von Grafenstein et al. The effect of botulinum toxin type D on the triggered and constitutive exocytosis/endocytosis cycles in cultures of bovine adrenal medullary cells

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130222